Generic Medicine Info
Indications and Dosage
Refractory acute lymphoblastic leukaemia
Child: As a single agent: 30 mg/m2 every 5 days to 180 mg/m2 wkly given over 30-60 min infusion. With other agents: 165 mg/m2 twice wkly for 8-9 doses with cytarabine or up to 250 mg/m2 wkly for 4-8 wk with vincristine and prednisone. Given as an infusion over 30-60 min.
Renal Impairment
Dose adjustment may be needed.
Hepatic Impairment
Dose adjustment may be needed.
Hypersensitivity to polyoxyethylated castor oil. Pregnancy and lactation. Severe hepatic and renal failure.
Special Precautions
Monitor CBC, electrolytes, renal and hepatic function at baseline and before each treatment. Avoid extravasation. Reduce dose in Down's syndrome, hepatic and renal impairment.
Adverse Reactions
Reversible alopoecia, nausea, vomiting, diarrhoea, mucositis, rash, fever, neurotoxicity, hepatic or renal dysfunction, infection, bleeding, secondary acute myeloid leukaemia. Hypotension upon rapid IV.
Potentially Fatal: Severe hypersensitivity reactions.
IV/Parenteral: D
Drug Interactions
Decreased teniposide concentration by phenytoin, phenobarbital, carbamazepine; increased teniposide toxicity with ciclosporin; increased risk of myelosuppression with colony stimulating factors, zidovudine. Interferes with GI absorption of other oral drugs eg. digoxin. Reduced response to vaccines.
Mechanism of Action: Teniposide has antineoplastic properties similar to etoposide. It appears to produce its cytotoxic effects by damaging DNA, thereby preventing or altering DNA synthesis. Given alone or with other antineoplastic agents in treatment of refractory acute lymphoblastic leukaemia.
Store 2-8°C.
MIMS Class
Cytotoxic Chemotherapy
Disclaimer: This information is independently developed by MIMS based on Teniposide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in